Biome Australia Sets New Sales Records and Advances Onshore Manufacturing

Record Sales and Market Leadership

Biome Australia Limited (ASX:BIO) closed FY26 on a high note, reporting record annual sales revenue of $23.9 million, a 30% increase over the prior year’s $18.4 million. June 2026 marked a company milestone as consumer sell-through of Activated Probiotics surpassed 100,000 units for the first time. This surge reflects strong demand fueled by Biome’s practitioner-led distribution model and growing pharmacy presence.

Notably, Biome Daily has ascended to become the number one probiotic product in Australian pharmacies by both units sold and dollar value. This leadership position underlines the brand’s growing consumer traction and sets a foundation for expanding the broader Activated Probiotics and Activated Therapeutics ranges domestically and internationally.

Onshore Manufacturing Deal to Boost Margins and Supply Chain

In a strategic move aligned with its Vision 27 growth plan, Biome signed a binding commercial manufacturing agreement with Specialty Probiotics Australia (SPA) to bring production of its Activated Probiotics range onshore. The deal requires no capital outlay and targets the first commercial batch for September 2026, with a full transition expected over 18 months.

This shift aims to structurally improve Biome’s cost of goods sold from the outset, reduce working capital tied up in inventory, and eliminate extended international freight lead times. Retaining European supply partnerships for EU markets will maintain supply-chain diversification while adding an Australian-made advantage across export markets.

Expanding Clinical Research and Intellectual Property

Biome continues to invest in its proprietary probiotic strain BMB18, lodging a patent application during the quarter. The company also expanded its BMB18 clinical trial from a single site to a multi-centre international program, adding Harokopio University of Athens alongside La Trobe University in Melbourne. Recruitment commenced at both sites for this randomised, double-blind, placebo-controlled study involving 240 participants.

BMB18’s clinical evaluation is expected to further differentiate Biome’s Activated Probiotics range, enhancing its competitive positioning in a crowded market.

Improved Cash Flow and Balance Sheet Position

Quarterly cash receipts rose to $5.9 million, up $1.1 million from the previous quarter and 61% ahead of the prior corresponding period. Biome delivered a net operating cash inflow of $708,000 for Q4 FY26, reversing prior quarters’ outflows and demonstrating operational discipline amid a challenging economic backdrop.

The company ended the quarter with $3.6 million in cash, an increase of $0.2 million quarter-on-quarter, while reducing drawn debt by $1 million to $1.9 million against total NAB facilities of $5 million. This financial flexibility supports ongoing growth initiatives, including the imminent onshore manufacturing rollout.

Outlook for FY27

Biome expects 1H FY27 to be its highest revenue-generating half-year on record, driven by new product launches across the Activated Probiotics range and continued international market expansion. Managing Director Blair Vega Norfolk highlighted the company’s capital-efficient growth strategy, combining debt reduction and cash growth with investments in manufacturing capability and clinical research.

As Biome transitions production onshore and advances its proprietary probiotic pipeline, the coming months will be critical to translating operational momentum into sustainable profitability and market share gains.